Debiopharm

Debiopharm is an independent Swiss biopharmaceutical company. It in-licenses early-stage compounds, takes them through preclinical and clinical development and regulatory submission, and then out-licenses them to partners for worldwide commercialization. Its activities include drug development, drug manufacturing and digital health investment, and its product page lists oxaliplatin and triptorelin.

Its customers are global pharmaceutical companies that commercialize its compounds. The website names commercialization partnerships with Ipsen, Ferring, Yakult, Takeda, Merck KGaA and ITM. Debiopharm describes itself as privately owned and not dependent on external investors.

The company was founded in 1979 by Dr. Rolland-Yves Mauvernay and is the Life Science division of Après-demain SA. It operates through three companies: Debiopharm International (drug development), Debiopharm Research & Manufacturing (drug manufacturing) and Debiopharm Innovation Fund (digital health investment). The website reports 420 employees and two locations in Switzerland, Lausanne and Martigny. Current open roles include regulatory affairs, clinical safety, biostatistics, quality assurance and a chemistry lab apprenticeship.

Product: Oncology and infectious-disease drug candidates and medicines, including oxaliplatin and triptorelin, developed for out-licensing to partners.